Gilead’s Trodelvy fails in lung cancer and raises new questions on antibody drug conjugate drugs. By Matthew Herper Jan. 22, 2024. Reprints. Yichuan Cao/Sipa USA via AP Images.

By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when ...

Gilead Sciences said on Monday a late-stage trial of its antibody-drug conjugate Trodelvy failed to show that it significantly improved survival for previously treated patients with advanced non ...

Gilead Sciences said on Monday its drug, Trodelvy, failed to significantly improve survival for previously treated patients with advanced non-small cell lung cancer (NSCLC) in a late-stage study ...

On the same day as it reported encouraging new data for its cancer drug Trodelvy, Gilead Sciences has agreed a deal to buy rights to the drug in Asia held by Chinese drugmaker Everest Medicines.

Many Gilead Sciences investors have lost faith in Trodelvy in HR-positive, HER2-negative breast cancer after disappointing data on tumor progression. But the antibody-drug conjugate has now made a ...

Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale. Gilead needs Arcellx more than ever.

Gilead Sciences' announced topline results from the Phase 3 TROPiCS-04 study on Trodelvy for metastatic urothelial cancer. The study did not meet the primary endpoint of overall survival but ...

Sept 7 (Reuters) - Gilead Sciences Inc's , opens new tab Trodelvy extended by 3.2 months the survival of patients with advanced stages of a common type of breast cancer, according to data released ...

Gilead is conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1. Sponsored Bank Accounts ...